Spring 2016
Nancy Hong Joins RiverVest
Nancy Hong, Ph.D., has joined RiverVest as managing director at our new San Diego office.   

Previously a principal with BioMed Ventures and an investment professional at Forward Ventures, Nancy brings valuable experience in successfully originating and managing investments in therapeutics, medical devices and diagnostics.

Fund III has Strong Start
Since closing on $80.2 million in commitments last May, RiverVest Venture Fund III has invested in eight portfolio companies.

Of those eight, RiverVest has co-founded three companies, led or co-led five of the financing rounds and was first institutional investor in the other three.  RiverVest's early involvement has enabled large ownership percentages, typically in the 10-20% range.

Recent Fund III portfolio company investments include Amplyx Pharmaceuticals, Viba Therapeutics and Spruce Biosciences .  Clinical progress in earlier Fund III companies is strong.
RiverVest's Fund II Performs in Top 5% of VC funds
RiverVest Fund II, with a DPI of 1.96x and a TVPI of 2.97x as of Dec. 31, 2015, is in the top 5% of 2006 vintage-year funds across all industry sectors, according to Cambridge Associates' Venture Capital Index and Benchmark Statistics report as of year end.
Portfolio News
Allakos, San Carlos, CA is developing antibodies that selectively target mast cells and eosinophils, important effector cells in a broad spectrum of allergic and inflammatory conditions and several rare proliferative diseases.
Amplyx Pharmaceuticals, a biopharma company in San Diego, CA, is developing novel broad-spectrum antifungal agents.
Otonomy, based in San Diego, CA, is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear.
Vasculox, St. Louis, MO, is a biotech company focused on the development of proprietary drugs for life-threatening disorders driven by CD47-mediated signaling pathways such as leukemia, lymphoma, solid tumors, pulmonary hypertension and delayed graft function following solid organ transplantation.
RiverVest Venture Partners® is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. Because of its extensive operating expertise, RiverVest is able to help entrepreneurs achieve near-term objectives that position their companies for exit.